BioMarin Pharmaceutical

$19.00

Want a discount? Become a member by purchasing Annual Subscription!
SKU: BMRN-1 Category:

Description

BioMarin Corporation: Will Its Strategic Portfolio Review Work? 

 

BioMarin Pharmaceutical recorded a 20% revenue growth in the fourth quarter of 2023 compared to Q4 of 2022. The company gained total revenue growth of 15% for the whole of 2023 versus the prior year. Non-GAAP earnings per share rose by 48% in Q4 2023, representing a 36% year-over[1]year increase. The company witnessed compelling results with VOXZOGO, particularly with its launch in achondroplasia, reporting 178% growth year-over-year. Furthermore, the firm started the enrolment process in Q4 for the pivotal program of VOXZOGO treating children with hypochondroplasia and has started discussions with global health authorities for its development programs in idiopathic short stature and several genetic short stature pathway conditions.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!